Corporate Tech Investors

Allogene Therapeutics

Allogene Therapeutics is a corporate venture capital group that partners with companies that are a good strategic fit.

Venture Investor Overview

Contact Information

Background Information

Overview

Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR TTM) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T (Auto CAR TTM) therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient.

Profile

Social Media

Company News

Facebook

YouTube

Last Transaction

2/17/2021

Transaction History

Our records indicate that Allogene Therapeutics invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Investor Contacts

Title

Name

Email & Social

Chief Executive Officer

David Chang

        

Funds

No fund closings have been recorded for this company.

Portfolio Companies

Allogene Therapeutics has invested in only one tech company, according to our database records. If we are missing a portfolio company, please let us know.

Browse more corporate investors:

Allianz X | Allscripts

Share this article

About Our Corporate Tech Investor Database

This corporate tech investor profile is powered by VentureDeal.com, a leading provider of corporate tech investing transaction data.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary